- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 7
- States / cities
- Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatitis B
- Interventions
- JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Infection
- Interventions
- Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 35
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Chronic Hepatitis C Virus Genotype 1
- Interventions
- BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Hepatitis C
- Interventions
- Eltrombopag, Antiviral therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more
- Conditions
- Hepatitis C
- Interventions
- Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
- Conditions
- Hepatitis C
- Interventions
- Peginterferon alfa-2a, Ribavirin, telaprevir
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hepatitis C
- Interventions
- Sofosbuvir, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Bakersfield, California + 55 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- Heckel Infrared Radiant Heat Device, cisplatin, gemcitabine, interferon-alpha, thermochemotherapy
- Device · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C
- Interventions
- PF-00868554, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more
- Conditions
- Hepatitis C Virus
- Interventions
- Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Peginterferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- peg-IFN-α, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hepatitis C, Chronic
- Interventions
- Pegylated-interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 18
- States / cities
- San Diego, California • Ventura, California • Bradenton, Florida + 13 more
- Conditions
- Hepatitis C
- Interventions
- Sofosbuvir, Placebo, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Hepatitis C
- Interventions
- INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Anaheim, California • La Jolla, California • San Francisco, California + 3 more
- Conditions
- Genotype 1 Chronic Hepatitis C
- Interventions
- GI-5005, Pegylated Interferon and Ribavirin
- Drug
- Lead sponsor
- GlobeImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin
- Drug · Biological
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 10
- States / cities
- Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more
- Conditions
- Hepatitis C
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland